ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,632.33
1.05%
Dow Jones
41,488.19
1.65%
Gold vs US Dollar
2,986.05
-0.17%
Brent Oil
70.69
-0.11%
Bitcoin
83,138.86
0.71%
Pepperstone
Advertisement
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Zai Lab Ltd (ZLAB)

  7. Zai Lab Ltd (ZLAB) News

Zai Lab (ZLAB)

Zai Lab Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ZLAB
DateTimeSourceHeadlineSymbolCompany
14/03/202521:13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZLABZai Lab Ltd
14/03/202521:13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZLABZai Lab Ltd
14/03/202521:13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZLABZai Lab Ltd
05/03/202521:11Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ZLABZai Lab Ltd
05/03/202516:22Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ZLABZai Lab Ltd
04/03/202522:11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZLABZai Lab Ltd
04/03/202522:11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZLABZai Lab Ltd
04/03/202516:27Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ZLABZai Lab Ltd
03/03/202516:49Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ZLABZai Lab Ltd
03/03/202512:30Business WireZai Lab Announces Participation in Investor Conferences in March 2025NASDAQ:ZLABZai Lab Ltd
28/02/202518:24Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ZLABZai Lab Ltd
28/02/202515:52Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ZLABZai Lab Ltd
27/02/202511:20Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ZLABZai Lab Ltd
27/02/202511:13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ZLABZai Lab Ltd
27/02/202511:00Business WireZai Lab Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate UpdatesNASDAQ:ZLABZai Lab Ltd
12/02/202514:25Edgar (US Regulatory)Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:ZLABZai Lab Ltd
28/01/202512:30Business WireZai Lab to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Recent Corporate Updates on February 27, 2025NASDAQ:ZLABZai Lab Ltd
23/01/202504:15Business WireZai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell Lung Cancer (SCLC)NASDAQ:ZLABZai Lab Ltd
17/01/202512:30Business WireZai Lab Announces Acceptance of New Drug Application for KarXT for the Treatment of SchizophreniaNASDAQ:ZLABZai Lab Ltd
15/01/202512:30Business WireZai Lab Announces Positive Topline Results for TIVDAK in the China Subpopulation of the Global Phase 3 innovaTV 301 Trial in Patients with Recurrent or Metastatic Cervical CancerNASDAQ:ZLABZai Lab Ltd
10/01/202512:30Business WireVertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and SingaporeNASDAQ:ZLABZai Lab Ltd
10/01/202512:30Business WireZai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and SingaporeNASDAQ:ZLABZai Lab Ltd
09/01/202523:30Business WireZai Lab Announces Strategic Partnership with MediLink Therapeutics to Develop a Novel LRRC15 Antibody-Drug ConjugateNASDAQ:ZLABZai Lab Ltd
03/01/202522:23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZLABZai Lab Ltd
13/12/202421:47Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZLABZai Lab Ltd
12/12/202412:30Business WireZai Lab Announces Participation in Investor Conference in January 2025NASDAQ:ZLABZai Lab Ltd
02/12/202412:02Business WireZai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic CancerNASDAQ:ZLABZai Lab Ltd
28/11/202404:05Business WireZai Lab Announces the Inclusion of AUGTYRO® (repotrectinib) for ROS1+ NSCLC and Other Updates in China’s National Reimbursement Drug ListNASDAQ:ZLABZai Lab Ltd
21/11/202409:00Business WireZai Lab and Pfizer Announce Strategic Collaboration on the Novel Antibacterial Drug XACDURO® (Sulbactam-Durlobactam)NASDAQ:ZLABZai Lab Ltd
18/11/202414:15Business WireZai Lab Announces Anticipated Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters' Option to Purchase Additional American Depositary SharesNASDAQ:ZLABZai Lab Ltd
 Showing the most relevant articles for your search:NASDAQ:ZLAB

Your Recent History

LSE
MSFT
1x Msft
ASX
HAL
Halo Technologies
TG
EVL
Evolus
AMEX
IEMG
MSCI Emerging Markets
TSXV
RMB.P
Rumbu
NYSE
MSGS
Madison Square Garden Sp...
AMEX
DTEC
ALPS Disruptive Technolo...
TG
TLX
Talanx
TG
9R8
Ordinary
LSE
80AR
Mdgh 26
TG
RW5
Brookfield Asset Managem...
COIN
HEXUSD
HEX
ASX
AV1
Adveritas
LSE
HYC
Hyder Consulting
AMEX
NVDX
T Rex 2X Long NVIDIA Dai...
AMEX
SBIO
ALPS Medical Breakthroug...
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2025 ADVFN PLC - All Rights Reserved

    Go Ad-Free

    Subscribe to Ad free and enjoy an ad-free experience

    No Ads

    Try Now

    Keep the Ads